Read the product record before an offer
The Vyleesi product record names the approved bremelanotide medicine. It also links the actions FDA has taken on that product.
FDA first approved it on June 21, 2019. The label used here is the FDA version revised in October 2026.
The current FDA medicine label is the main source for its approved use and warnings. It also contains the trial tables and a section written for people taking the drug.
Read the approved use first. Then find the topic behind your question. The label is long, so take it a part at a time. Mark the words that are hard to follow. Ask the prescriber or pharmacist to put them in plain words.
Older copies of the label checked for this handbook left out the new milk study. It appears in the FDA label from October 2026.
The new section reports that little drug passed into milk after a single injection. The study did not test effects on babies or on the milk supply.
Read the comparison and its limits together
The RECONNECT trial report compares the drug with a placebo, a dummy injection. The women in the study were before menopause and had HSDD, or distressing low desire.
The extra average changes were modest: 0.35 points more desire and 0.33 points less distress than with the dummy injection, based on women’s questionnaire answers. Those group scores do not tell what a particular woman would notice in daily life.
For the count of satisfying sexual events, the study did not find a clear added gain over placebo.
Read those results together. A favorable score is only part of the answer. A paper can tell what happened in the group. It cannot tell exactly what will happen for you.
The longer extension report followed women who chose to take part, without a dummy-treatment group. It cannot establish lasting benefit over placebo.
For the earlier work in men, the nasal-form study used a form that differs from the approved injection.
The journal concern notice raises doubt about another often-cited study in men. No claimed benefit rate from that disputed report is used here.
Use care standards for questions about the route
FDA’s compounding questions and answers and account of compounding risks set out what compounding means. They also make clear that a compounded drug differs from an approved finished product.
As checked on November 3, 2026, compounded drugs do not receive FDA approval. FDA does not check their quality, benefit and safety before they reach the market.
The medical-board group’s remote-care policy sets out how an assessment can gather more history. It also covers referral when remote care cannot complete the work.
It is a model for state boards to use. It is not a law that binds every state.
The report on prescribing from the Federation of State Medical Boards became the group’s agreed guidance in May 2026. It is advice for state boards, not a new nationwide law. It covers questions raised when people seek care through a website.
For a license check, the list of state medical boards and FDA’s state pharmacy-search page lead to the public records.
Those records can show a license. They do not grade the care or endorse a given prescription.
Find the record that fits
For a drug question, name the product and the part of the label. For a study claim, name the group and what was compared. For a care question, name the person or pharmacy and the place whose rules apply. These details make an answer easier to check.
Use these links to look at the source of an answer. Find the part that deals with your question. Does it describe the same product and the same use? Mark what you want to ask about, so the next discussion can go straight to that part.
If a claim seems to promise more than a record says, ask about the gap. Which words in the source support the claim? A useful answer can state a limit. It can also show where a personal assessment is needed.